Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 8
2003 8
2004 8
2005 3
2006 3
2007 5
2008 6
2009 8
2010 7
2011 3
2012 9
2013 3
2014 3
2015 8
2016 7
2017 3
2018 5
2019 2
2020 4
2021 6
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Results by year

Filters applied: . Clear all
Page 1
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.
Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Yoshihara S, Manabe M, Ichihara H, Mugitani A, Aoyama Y, Nakao T, Hirose A, Hino M, Ueda S, Takenaka K, Masuko T, Akashi K, Maruno T, Uchiyama S, Takamatsu S, Wada N, Morii E, Nagamori S, Motooka D, Kanai Y, Oji Y, Nakagawa T, Kijima N, Kishima H, Ikeda A, Ogino T, Shintani Y, Kubo T, Mihara E, Yusa K, Sugiyama H, Takagi J, Miyoshi E, Kumanogoh A, Hosen N. Hasegawa K, et al. Among authors: tsuboi a. Sci Transl Med. 2022 Feb 16;14(632):eaax7706. doi: 10.1126/scitranslmed.aax7706. Epub 2022 Feb 16. Sci Transl Med. 2022. PMID: 35171652
Imaging Assessment of Tumor Response in the Era of Immunotherapy.
Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Nakata J, et al. Among authors: tsuboi a. Diagnostics (Basel). 2021 Jun 5;11(6):1041. doi: 10.3390/diagnostics11061041. Diagnostics (Basel). 2021. PMID: 34198874 Free PMC article. Review.
WT1 peptide vaccine for the treatment of cancer.
Oka Y, Tsuboi A, Oji Y, Kawase I, Sugiyama H. Oka Y, et al. Among authors: tsuboi a. Curr Opin Immunol. 2008 Apr;20(2):211-20. doi: 10.1016/j.coi.2008.04.009. Epub 2008 May 24. Curr Opin Immunol. 2008. PMID: 18502632 Review.
WT1 peptide vaccine as a paradigm for "cancer antigen-derived peptide"-based immunotherapy for malignancies: successful induction of anti-cancer effect by vaccination with a single kind of WT1 peptide.
Oka Y, Tsuboi A, Fujiki F, Li Z, Nakajima H, Hosen N, Shirakata T, Nishida S, Oji Y, Kawase I, Sugiyama H. Oka Y, et al. Among authors: tsuboi a. Anticancer Agents Med Chem. 2009 Sep;9(7):787-97. doi: 10.2174/187152009789056958. Epub 2009 Sep 1. Anticancer Agents Med Chem. 2009. PMID: 19538172 Review.
WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
Oji Y, Inoue M, Takeda Y, Hosen N, Shintani Y, Kawakami M, Harada T, Murakami Y, Iwai M, Fukuda M, Nishida S, Nakata J, Nakae Y, Takashima S, Shirakata T, Nakajima H, Hasegawa K, Kida H, Kijima T, Morimoto S, Fujiki F, Tsuboi A, Morii E, Morita S, Sakamoto J, Kumanogoh A, Oka Y, Okumura M, Sugiyama H. Oji Y, et al. Among authors: tsuboi a. Int J Cancer. 2018 Jun 1;142(11):2375-2382. doi: 10.1002/ijc.31253. Epub 2018 Jan 21. Int J Cancer. 2018. PMID: 29322496 Free article.
104 results